November 12, 2024 ALS-focused Trace Neuroscience launches with $100 million in capital Portfolio Company News Read more
October 7, 2024 Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney Portfolio Company News Read more
October 2, 2024 With $115M more, Triveni accelerates immune drug work Portfolio Company News Read more
October 1, 2024 Ron Renaud’s new obesity biotech, Kailera, has $400M to go straight to Phase 3 Portfolio Company News Read more